The latest price target for Pacira BioSciences (NASDAQ:PCRX) was reported by Barclays on February 28, 2025. The analyst firm set a price target for $24.00 expecting PCRX to rise to within 12 months (a possible 2.50% upside). 34 analyst firms have reported ratings in the last year.

The latest analyst rating for Pacira BioSciences (NASDAQ:PCRX) was provided by Barclays, and Pacira BioSciences maintained their overweight rating.

The last upgrade for Pacira BioSciences Inc happened on January 30, 2025 when Truist Securities raised their price target to $25. Truist Securities previously had a sell for Pacira BioSciences Inc.

The last downgrade for Pacira BioSciences Inc happened on August 13, 2024 when Truist Securities changed their price target from $30 to $8 for Pacira BioSciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacira BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacira BioSciences was filed on February 28, 2025 so you should expect the next rating to be made available sometime around February 28, 2026.

While ratings are subjective and will change, the latest Pacira BioSciences (PCRX) rating was a maintained with a price target of $17.00 to $24.00. The current price Pacira BioSciences (PCRX) is trading at is $23.42, which is within the analyst’s predicted range.